NeuroMetrix to Exhibit at American Diabetes Association 72nd Scientific Sessions
WALTHAM, Mass.--(BUSINESS WIRE)--May. 31, 2012--
NeuroMetrix, Inc. (Nasdaq: NURO),
www.neurometrix.com,
a medical device company focused on the diagnosis and treatment of the
neurological complications of diabetes, reported today that it will
exhibit and participate in the
American Diabetes Association (ADA) 72
nd
Scientific Sessions. The ADA Scientific Sessions will be held on
June
8-12 in
Philadelphia at the
Pennsylvania Convention Center.
NeuroMetrix will feature the NC-stat® DPNCheck™, a medical
device providing a fast, accurate, and quantitative point-of-care test
for the detection of systemic neuropathies, such as diabetic peripheral
neuropathy (DPN). DPN affects over 50% of people with diabetes and can
trigger foot ulcers that may require amputation, as well as severe and
debilitating foot and lower leg pain known as painful diabetic
neuropathy. Over 500 NC-stat DPNCheck devices have been shipped since
the fourth quarter of 2011. Live demonstrations of NC-stat DPNCheck will
be conducted at the NeuroMetrix booth.
The clinical benefits of sural nerve conduction measurement at the
point-of-care include:
-
Early detection of DPN, even in the absence of clinical symptoms and
signs
-
Help with confirmation or rule-out of DPN and quantification of
severity
-
Monitoring changes in DPN over time and in response to treatment
The company will also introduce the SENSUS™ pain management device.
SENSUS is a transcutaneous electrical nerve stimulator uniquely designed
to be used in managing chronic pain in the foot and lower leg, such as
due to painful diabetic neuropathy. Several SENSUS devices will be on
display at the NeuroMetrix booth to help physicians and other interested
parties better understand how this novel device can benefit their
diabetic patients suffering from painful diabetic neuropathy. SENSUS is
the subject of a recent 510(k) premarket approval filing with the Food
and Drug Administration (FDA) and is not currently available for
commercial distribution.
Additional company activities will include presentation of a scientific
poster titled “Reproducibility of a Rapid Point-of-Care Sural Nerve
Conduction Test” by Dr. Kenneth J. Snow, NeuroMetrix Chief Medical
Officer. This study demonstrates that NC-stat DPNCheck test results are
highly reproducible thereby supporting use of the device in monitoring
development and progression of DPN. The company will also conduct a
meeting of its scientific advisory board consisting of international
leaders in the detection, management, and treatment of the neurological
complications of diabetes.
NeuroMetrix senior management including Dr. Shai N. Gozani, President
and CEO, Thomas T. Higgins, Senior Vice President and CFO, and K.
Balachandran, Senior Vice President and COO will be attending the
meeting. Attendees are encouraged to visit NeuroMetrix at booth #543.
About NeuroMetrix
NeuroMetrix is an innovative medical device company that develops and
markets home use and point-of-care devices, associated consumables, and
support software for the treatment and management of diabetes and its
complications. The company is focused on nerve related complications of
diabetes, called diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot
ulcers that may require amputation, cause disabling pain, and increase
the risk of falling in the elderly. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company’s products are used by physicians and other clinicians, in
retail health settings such as pharmacies, and by managed care
organizations to optimize patient care and reduce healthcare costs. The
company markets the NC-stat® DPNCheck™ device, which is a
rapid, accurate, and quantitative point-of-care test for diabetic
neuropathy. This product is used to detect diabetic neuropathy at an
early stage and to guide treatment. The company is in late stage
development of SENSUS™, a pain management device that will be used to
treat painful diabetic neuropathy, a form of chronic intractable pain.
Currently, painful diabetic neuropathy is treated pharmacologically,
which is a $2 billion annual market. The company has additional
therapeutic products in its pipeline. For more information, please visit http://www.neurometrix.com.
Source: NeuroMetrix, Inc.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
